Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Proto Labs IncPRLB · Entity 4553 | Chief Operations Officer | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Proto Labs Inc
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,683 |
Ending reported balance
After 2026-05-12 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 3,756 · Balance 30,942 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Row 2 · 2026-05-11 · Exercise / conversion · Acquired 3,677 · Balance 34,619 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Row 3 · 2026-05-11 · Sale · Disposed 7,433 · Balance 27,186 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F2: Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2026-05-12 · Exercise / conversion · Acquired 1,928 · Balance 29,114 Row 5 · 2026-05-12 · Exercise / conversion · Acquired 1,557 · Balance 30,671 Row 6 · 2026-05-12 · Exercise / conversion · Acquired 4,042 · Balance 34,713 Row 7 · 2026-05-12 · Sale · Disposed 1,613 · Balance 33,100 F3: Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 8 · 2026-05-12 · Sale · Disposed 4,198 · Balance 28,902 F4: Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 9 · 2026-05-12 · Sale · Disposed 3,576 · Balance 25,326 F5: Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 10 · 2026-05-12 · Sale · Disposed 6,643 · Balance 18,683 F6: Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2033-02-14 | Direct | 3,856 |
Reported balance
After 2026-05-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-11 · Exercise / conversion · Disposed 3,756 · Balance 3,856 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.52 · Expires 2034-02-13 | Direct | 3,778 |
Reported balance
After 2026-05-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-11 · Exercise / conversion · Disposed 3,677 · Balance 3,778 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F8: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2033-02-14 | Direct | 1,928 |
Reported balance
After 2026-05-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-12 · Exercise / conversion · Disposed 1,928 · Balance 1,928 F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.61 · Expires 2035-02-25 | Direct | 4,674 |
Reported balance
After 2026-05-12 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-12 · Exercise / conversion · Disposed 1,557 · Balance 4,674 F9: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.40 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-05-12 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-05-12 · Exercise / conversion · Disposed 4,042 · Balance 0 F10: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.
F2: Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested.
F8: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
F9: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
F10: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,042 | $0.00 Strike: $59.40 | $0.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · derivative · entry 15 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,042 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,557 | $0.00 Strike: $39.61 | $0.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · derivative · entry 14 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,674 Underlying: Common Stock · 1,557 shares Expires 2035-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,928 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · derivative · entry 13 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,928 Underlying: Common Stock · 1,928 shares Expires 2033-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 6,643 | $70.30 | $466,975.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 10 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,683 F6 · price: Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 3,576 | $69.78 | $249,541.50 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 9 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,326 F5 · price: Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 4,198 | $68.70 | $288,390.43 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 8 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,902 F4 · price: Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 1,613 | $67.58 | $109,007.67 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 7 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,100 F3 · price: Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 4,042 | $59.40 | $240,094.80 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 6 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 1,557 | $39.61 | $61,672.77 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 5 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 1,928 | $33.84 | $65,243.52 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 4 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,677 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · derivative · entry 12 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,778 Underlying: Common Stock · 3,677 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F8 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,756 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · derivative · entry 11 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,856 Underlying: Common Stock · 3,756 shares Expires 2033-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F7 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 7,433 | $70.26 | $522,251.50 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,186 F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F2 · price: Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 3,677 | $33.52 | $123,253.04 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:40 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 3,756 | $33.84 | $127,103.04 |
DisclosureSEC source: 0001628280-26-034651 · wk-form4_1778704834.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:33 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-26-032958 · wk-form4_1778272404.xml · derivative · entry 5 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,455 Underlying: Common Stock · 100 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:33 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001628280-26-032958 · wk-form4_1778272404.xml · derivative · entry 4 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,612 Underlying: Common Stock · 100 shares Expires 2033-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:33 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 200 | $70.00 | $14,000.00 |
DisclosureSEC source: 0001628280-26-032958 · wk-form4_1778272404.xml · nonDerivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,186 F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:33 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 100 | $33.52 | $3,352.00 |
DisclosureSEC source: 0001628280-26-032958 · wk-form4_1778272404.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:33 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 100 | $33.84 | $3,384.00 |
DisclosureSEC source: 0001628280-26-032958 · wk-form4_1778272404.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 4,404 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0001628280-26-012831 · wk-form4_1772226970.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,404 Underlying: Common Stock · 4,404 shares Expires 2036-02-25 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 25, 2027, and on each February 25th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 531 | $62.63 | $33,256.53 |
DisclosureSEC source: 0001628280-26-012831 · wk-form4_1772226970.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,186 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 2,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012831 · wk-form4_1772226970.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,717 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 25, 2027, and on each February 25th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:37 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 5,000 | $66.46 | $332,315.00 |
DisclosureSEC source: 0001628280-26-009129 · wk-form4_1771450661.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,302 F1 · kind: This transaction was executed pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on August 15, 2025. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on February 17, 2026, with sale prices ranging from $66.01 to $66.87 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:37 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 1,540 | $67.52 | $103,980.80 |
DisclosureSEC source: 0001628280-26-009129 · wk-form4_1771450661.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,302 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:50 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 2,684 | $53.18 | $142,735.12 |
DisclosureSEC source: 0001870293-26-000004 · form4-02122026_090223.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,842 Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 21:53 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 2,500 | $60.00 | $150,000.00 |
DisclosureSEC source: 0001628280-26-006501 · wk-form4_1770674010.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,526 F1 · kind: This transaction was executed pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on August 15, 2025. Read SEC document |
| January 29, 2026 Filed Feb 4, 2026 23:16 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 8,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005553 · wk-form4_1770246977.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,026 Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:37 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001870293-25-000004 · wk-form4_1764196640.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,664 Underlying: Common Stock · 3,048 shares Expires 2033-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:37 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 3,048 | $50.17 | $152,930.66 |
DisclosureSEC source: 0001870293-25-000004 · wk-form4_1764196640.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,898 F2 · shares: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F3 · price: Reflects the weighted average price of 3,048 shares of Common Stock of the issuer sold by the Reporting Person in multiple transactions on November 25, 2025 with sale prices ranging from $50.00 to $50.53 per share. The Reporting Person undertakes to provide upon request by U.S. Securities and Exchange Commission staff, the issuer, or a securityholder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:37 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 3,048 | $33.84 | $103,144.32 |
DisclosureSEC source: 0001870293-25-000004 · wk-form4_1764196640.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 57 shares of Common Stock of the issuer purchased on November 15, 2025 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| November 25, 2025 Filed Dec 3, 2025 23:13 UTC Amendment | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001870293-25-000007 · wk-form4a_1764803630.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. F5 · derivative.expiration_date: This amendment reflects an adjustment to the expiration date of the Employee Stock Options to correct a clerical error in the reporting person's Form 4 filed on November 25, 2025. All transaction details were accurately reported on the original Form 4. Read SEC document |
| November 25, 2025 Filed Dec 3, 2025 23:13 UTC Amendment | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 3,048 | $50.17 | $152,930.66 |
DisclosureSEC source: 0001870293-25-000007 · wk-form4a_1764803630.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,898 F2 · shares: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F3 · price: Reflects the weighted average price of 3,048 shares of Common Stock of the issuer sold by the Reporting Person in multiple transactions on November 25, 2025 with sale prices ranging from $50.00 to $50.53 per share. The Reporting Person undertakes to provide upon request by U.S. Securities and Exchange Commission staff, the issuer, or a securityholder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Dec 3, 2025 23:13 UTC Amendment | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 3,048 | $33.84 | $103,144.32 |
DisclosureSEC source: 0001870293-25-000007 · wk-form4a_1764803630.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 57 shares of Common Stock of the issuer purchased on November 15, 2025 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:39 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 204 | $40.87 | $8,337.48 |
DisclosureSEC source: 0001628280-25-027300 · wk-form4_1747946362.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,841 F1 · balance_after: Includes 63 shares of Common Stock of the issuer purchased on May 15, 2025 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 21:33 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 6,231 | $0.00 Strike: $39.61 | $0.00 |
DisclosureSEC source: 0001628280-25-008704 · wk-form4_1740691994.xml · derivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,231 Underlying: Common Stock · 6,231 shares Expires 2035-02-25 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 21:33 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 6,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008704 · wk-form4_1740691994.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,982 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:42 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 1,696 | $45.03 | $76,370.88 |
DisclosureSEC source: 0001628280-25-006145 · wk-form4_1739918569.xml · nonDerivative · entry 3 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,039 Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:42 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 580 | $45.03 | $26,117.40 |
DisclosureSEC source: 0001628280-25-006145 · wk-form4_1739918569.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,735 Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:42 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 1,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-006145 · wk-form4_1739918569.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,315 F1 · balance_after: Includes 70 shares of Common Stock of the issuer purchased on November 15, 2024 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:24 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 336 | $31.81 | $10,688.16 |
DisclosureSEC source: 0001437749-24-018009 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,351 F1 · balance_after: Includes 282 shares of Common Stock of the issuer purchased on May 15, 2024 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 7,555 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,555 Underlying: Common Stock · 7,555 shares Expires 2034-02-13 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 8,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,405 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:06 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 1,070 | $33.52 | $35,866.40 |
DisclosureSEC source: 0001437749-24-004398 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 F1 · balance_after: Includes 349 shares of Common Stock of the issuer purchased on May 15, 2023 and 197 shares of Common Stock of the issuer purchased on November 15, 2023, through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 5 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 F5 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 7,712 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 4 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 Underlying: Common Stock · 7,712 shares Expires 2033-02-14 F4 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantPerformance Stock Units · Derivative | 4,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,064 Underlying: Common Stock · 4,064 shares Expires 2025-12-31 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:09 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 8,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · nonDerivative · entry 2 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,724 F2 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:09 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 340 | $34.23 | $11,638.20 |
DisclosureSEC source: 0001437749-23-003516 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,597 F1 · balance_after: Includes 262 shares of Common Stock of the issuer purchased on November 15, 2022 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:13 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 771 | $45.68 | $35,219.28 |
DisclosureSEC source: 0001437749-22-013565 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,675 F1 · balance_after: Includes 225 shares of Common Stock of the issuer purchased on May 15, 2022 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.